|
Drug | EMA-approved indication in solid tumours | Main targets | Role in redox system |
|
Afatinib | EGFR-mutated NSCLC | EGFR | Chronic oxidative stress associated with resistance. |
|
Axitinib | RCC | VEGFR1–3, PDGFR, c-Kit | Oxidative stress-mediated genotoxic effects. |
|
Bevacizumab | CRC Breast cancer NSCLC Ovarian cancer Peritoneal cancer RCC | VEGF | Increases ROS levels. Combined with autophagy inhibitor enhances ROS levels and apoptosis. |
|
Cetuximab | HNSCC CRC | EGFR | Reduces the amount of GSH by internalizing EGFR and glutamine transport. Decreases Nox1 and Nox1-related effect of oxaliplatin. |
|
Crizotinib | ALK-positive NSCLC | ALK, c-MET | Increased O2•− production linked with cardiotoxicity. Prx II up-regulation associated with resistance. |
|
Erlotinib | EGFR-mutated NSCLC Pancreatic cancer | EGFR | Increases ROS-mediated apoptosis in HNSCC and NSCLC. |
|
Gefitinib | EGFR-mutated NSCLC | EGFR | Increases oxidative stress linked to EMT and cardiotoxicity. NFE2L2/Keap1-axis related to treatment resistance. |
|
Imatinib | GISTs | PDGFRα, KIT, ABL, CSF-1 receptor | Induces ROS-dependent apoptosis in melanoma. |
|
Lapatinib | HER2-positive breast cancer | HER1, HER2 | Increases ROS; low ROS levels linked with resistance, which may be overcome with antioxidant mimics. |
|
Pazopanib | RCC, sarcomas | Various kinases, for example, VEGFR1–3, (PDGFR-α and PDGFR-β), c-Kit, FGFR-1, and FGFR-3 | May induce oxidative DNA damage-mediated erythrocyte apoptosis. |
|
Rituximab | Non-Hodgkin’s lymphoma | CD-20 | CD20 stimulation leads to the production of O2•−. |
|
Sorafenib | HCC, RCC, radioiodine-refractory thyroid cancer | Various kinases, for example, VEGFR-2 and VEGFR-3, PDGFR-β, and RAF-kinases | Increases oxidative stress, which possibly is a predictive factor for sorafenib |
|
Sunitinib | GISTs, pancreatic NET, RCC | Various kinases, for example, VEGFR1–3, (PDGFR-α and PDGFR-β), c-Kit | Enhances antioxidant defence, decreases NOS activity and expression. |
|
Trastuzumab | HER2-positive breast cancer and HER2-positive gastric cancer | HER2 dimerization | Regulatory loop with NFE2L2 NFE2L2 increases trastuzumab resistance. |
|
Vemurafenib | BRAF (V600E) mutated melanoma | BRAF V600E | Increases NO• and O2•− production increases depolarization of mitochondrial membranes. Induces PGC1α |
|